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Most human cancers derive from a single cell tar-
geted by genetic and epigenetic alterations that ini-
tiate malignant transformation. Progressively, these
early cancer cells give rise to different generations
of daughter cells that accumulate additional muta-
tions, acting in concert to drive the full neoplastic
phenotype1,2. As we have currently deciphered
many of the gene pathways disrupted in cancer, our
knowledge about the nature of the normal cells
susceptible to transformation upon mutation has
remained more elusive. 
Adult stem cells are those that show long-term
replicative potential, together with the capacities of
self-renewal and multi-lineage differentiation. The-
se stem cell properties are tightly regulated in nor-
mal development, yet their alteration may be a crit-
ical issue for tumorigenesis. This concept has arisen
from the striking degree of similarity noted be-
tween somatic stem cells and cancer cells, includ-
ing the fundamental abilities to self-renew and dif-
ferentiate. Given these shared attributes, it has been
proposed that cancers are caused by transforming
mutations occurring in tissue-specific stem cells3-9.
This hypothesis has been functionally supported by
the observation that among all cancer cells within a
particular tumor, only a minute cell fraction has the
exclusive potential to regenerate the entire tumor
cell population3,10-13; these cells with stem-like
properties have been termed cancer stem cells.
Cancer stem cells can originate from mutation in
normal somatic stem cells that deregulate their
physiological programs. Alternatively, mutations
may target more committed progenitor cells or
even mature cells, which become reprogrammed to
acquire stem-like functions14,15 In any case, mutat-
ed genes should promote expansion of stem/pro-
genitor cells, thus increasing their predisposition to
cancer development by expanding self-renewal and
pluripotency over their normal tendency towards
relative quiescency and proper differentiation.
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The ability of the stem cells to produce progeny that
expresses different mature phenotypes is called po-
tential or plasticity. Pluripotent embryonic stem cells
can give rise to all of the differentiated tissues of the
body whereas multipotent somatic stem cells have
the capacity to form many but not all different cell
types. Some childhood tumors have provided a link
between embryonic stem cells and cancer16-18. Both
neuroblastoma (which arises from fetal neural crest
cells of the sympathetic nervous system) and Wilms
tumor (which arises from embryonic cells of the kid-
ney) are caused by mutations occurring in embryonic
stem cells, giving rise to tumors composed of a mixture
of undifferentiated spindle cells, immature epithelial
tubules and more differentiated cells. Similarly, terato-
carcinomas are made up of a variety of differentiated
cell types as well as of embryonic and fetal tissue
cells18,19. Because these normal embryonic cells
physiologically differentiate with age and eventually
disappear, neuroblastoma, teratocarcinomas and Wilms
tumors only affect to young children16-18,20. However,
the majority of cancers occurring in adults are de-
rived from multipotent or pluripotent (somatic) stem
cells, some of which have been recently discovered. 
Here we review the role of the cancer stem cells iden-
tified in different hematopoietic and solid tumors, fo-
cusing on the molecular networks that govern their
homeostatic programs. We will additionally address
emerging new concepts and controversial issues of
cancer stem cell biology. Last, the potential implica-
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tion of cancer stem cells in the development of lym-
phoid malignancies will be discussed.
HEMATOPOIETIC STEM CELLS AS TARGETS
OF TRANSFORMING MUTATION
IN LEUKEMIA
Early bone-marrow reconstitution experiments in
immunocompromised mice revealed the existence of
the hematopoietic stem cells (HSCs)21,22. Recently,
many tissue-specific stem cells have been identi-
fied23-27. Stem cells share the characteristics of un-
limited self-renewal, which maintains or expands the
stem-cell population, and multi-lineage differentia-
tion, which generates and regenerates tissues27. Yet
another defining characteristic of stem cells is their
limited replication frequency (quiescence) compared
to their more proliferative progreny28. Although ini-
tial evidence for the concept of cancer stem cells also
came from early studies10,29-31. solid experimental
analysis have demonstrated their existence only re-
cently. Two pioneering reports showed that despite
most of the tumor cells obtained from patient with
acute myeloid leukemia (AML) were unable to prolif-
erate extensively, a small subset were capable of
transferring the leukemia to immunocompromised
mice. These leukemia-initiating stem cells (LSCs)
were prospectively identified as having a CD34+
CD38- phenotype, resembling normal HSCs11,32,33. By
contrast, CD34+CD38+ leukemic cells were not able
to propagate the leukemia. Notably, on each of the
morphological and genetic subtypes of AML, only the
CD34+CD38- cell population retained the capacity to
transfer the leukemia in vivo32. These data indicate
that AMLs exhibiting different stages of differentia-
tion are originated from a common LSC that shares
similar cell-surface markers with normal long-term
HSCs. Subsequent studies have characterized in detail
the phenotypes of normal HSCs and LSCs. Besides a
CD34+CD38- phenotype, both lack expression of the
lineage markers CD71 and HLA-DR32,33. Notably,
LSCs also lack expression of CD90 and the stem cell
factor receptor CD117 (c-Kit) whereas they had high
expression of the interleukin-3-alpha receptor
CD12334,35. However, despite a common immuno-
phenotype, LSCs are not functionally homogeneous
but instead, resembling the normal hematopoiesis,
form a hierarchy of cells that differ in their self-re-
newal potential36. The similarities between HSCs and
LSCs strongly suggest that HSCs are the source of LSCs
when targeted by oncogenic mutations. Nevertheless,
these mutations may also target progenitor cells that
become de novo leukemia stem-like cells (fig. 1). 
Additional evidence supports that AML is a progres-
sive model of cancer resulting from mutations in
HSCs and their progeny. The t(8;21)(q22;q22) is the
most frequent chromosomal translocation in AML,
resulting in a chimeric AML1-ETO gene fusion. In
HSCs isolated from patients with AML in complete re-
mission, AML1-ETO transcripts were found in a frac-
tion of normal bone marrow HSCs37. These cells did
not show leukemic properties, and normally differen-
tiated to myeloid and erythroid cells. Consequently,
the t(8;21) occurred in normal HSCs suggesting that it
was the additional mutations in a subset of HSCs or
their progeny which led to leukemia development. A
different experimental approach has investigated the
transformation capacity of a variety of oncogenes in-
volved in human leukemia when ectopically ex-
pressed into the different HSC compartments. Short-
lived myeloid progenitors transduced with MLL-ENL
or MOZ-TIF2 oncogenic fusions generated AML with
similar latencies and characteristics than those ob-
served in long-term HSC models15,38. Notably, this
observation was not expanded to BCR-ABL or MLL-
GAS7 gene fusions, which did not transformed com-
mitted murine hematopoietic progenitors38,39. Ac-
cording to these data, some but not all oncogenes are
capable of mediate similar leukemic transformation
in both HSCs and committed progenitors. More re-
cently, Eguchi et al expressed the two variants of the
TEL-TRKC fusion gene, which are found in leuke-
mias and solid tumors, into the mouse stem cell com-
partment. Results showed that the leukemia form of
TEL-TRKC enhanced hematopoietic stem cell renew-
al and originated leukemia whereas the solid tumor
variant of TEL-TRKC elicited impairment of hema-
topoiesis but did not induce cancer40. Thus, related
oncogenic fusion genes similarly expressed in stem
cells may produce diverse cell type-specific develop-
mental impacts. This interesting finding might ex-
plain the phenotypic diversity of human leukemia de-
spite having identical chromosomal rearrangements.
Functional studies have also been conducted in chro-
nic myeloid leukemia (CML), a disease of HSCs that
undergo hierarchical differentiation, thus resulting in
a vast majority of differentiated CML blood cells,
whereas a rare cell fraction resembling normal HSCs
is responsible for disease maintenance. CML cells al-
so have the potential to generate acute leukemias of
myeloid and lymphoid lineage during the blast cri-
sis41,42. At the molecular level, CML is characterized
by the BCR-ABL oncogenic fusion, which can be de-
tected through all lineages of differentiation of CML
cells, including the CD34+ stem cell compartment,
pointing out to this leukemia as a prototype of stem
cell disorder41-44. However, recent studies have indi-
cated that the granulocyte-macrophage progenitor
cells from patients with CML in blast crisis presented
self-renewal capacity, a cell compartment which nor-
mally has not this property45. These data suggest that
despite BCR-ABL fusion targets CD34+ stem cells and
originate CML in chronic phase, progenitor cells are
also responsible for leukemic transformation in the
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blast crisis, demonstrating that the hierarchy of
leukemia-initiating stem cells can change during the
progression of the disease. 
In contrast to myeloid leukemia, progress towards the
identification of the stem cell of origin in acute lym-
phoblastic leukemia (ALL) has been more limited.
The best characterized leukemia subtype is ALL with
BCR-ABL chimeric protein (ALL-Ph+). Functional
studies in a mouse model of ALL-Ph+ demonstrated
that the only fraction of cells capable of engrafting
NOD/SCID mice were CD34+/CD38- cells46. These
data indicate that primitive progenitor cells rather
than more committed lymphoid cells are targeted by
BCR-ABL gene rearrangement in ALL. A different
study used human leukemic cells from patients with
other subgroups of ALL47,48. ALL cells with a CD34+
CD10- phenotype were capable of transferring leuke-
mia to NOD/SCID mice. The engrafted cells showed the
same phenotype of the patients at diagnosis (CD34+,
CD10+, CD19+), indicating that CD34+ CD10- pro-
genitor cells differentiated in vivo. Further functional
characterization studies should determine whether
multipotent HSCs or more committed progenitors are
commonly targeted in the distinct ALL molecular
subgroups or by contrast, specific ALL gene rear-
rangements occur in different stem cell populations.
CANCER STEM CELLS AS THE ORIGIN
OF SOLID TUMORS
The leukemia experimental studies were subsequent-
ly extended to include epithelial cancers. Using a
model of human breast cancer cells obtained from
primary tumors and pleural metastatic effusions that
were grown in non-obese diabetic, severe combined
immunodeficient (NOD/SCID) mice, investigators
distinguished the tumor-initiating cells from the non-
tumorigenic cells based on their cell phenotype12.
LTR-SC
STR-SC
MATURE BLOOD
CELLS LEUKEMIA
LSC
CMP
CLP
LP
Fig. 1. Stem cells as targets of mutation in leukemia development. LTR-SC, Long-term repopulating stem cell; STR-SC, short-
term repopulating stem cell; CMP, common myeloid progenitors; CLP, common lymphoid progenitors; LSC, leukemia stem
cell; LP, leukemia progenitors.
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Tumor-initiating cells expressed CD44 but little or no
CD24. As few as 100 cells with this phenotype were
able to form tumors in mice, whereas thousands of
tumor cells with other different phenotypes failed. In
addition, these cells could be serially passaged from
mouse to mouse, and each time the new tumors con-
tained the diverse mixed population of tumorigenic
CD44+CD24-/low and non-tumorigenic cells present
in the initial tumor12,49. The possibility to separate tu-
morigenic and non-tumorigenic cells will allow elu-
cidating the molecular pathways that account for
their different oncogenic potential.
The embryonic features present in several types of
brain tumors have suggested that they originate from
transformed neural stem or progenitor cells. The best
example is childhood medulloblastoma, which is
considered a failure of the process of differentiation of
the neural primitive pluripotential cerebellum stem
cells18. In adult brain tumors, similar conclusions
have been reached by three different groups50-52.
Singh and colleagues prospectively identified a cell
subpopulation from brain tumors expressing the hu-
man neural stem cell marker CD133 that exhibited
stem cell properties in vitro and in vivo. These
CD133+ cells were the only cell fraction capable of
tumor initiation in NOD-SCID mouse13. Injection of
as few as 100 cells with this phenotype generated tu-
mors that were serially transplanted, whereas
CD133- cells were unable to transfer the neoplasm.
These cells were isolated from high and low grade tu-
mors from both children and adults, suggesting that
the principles of stem cell leukemogenesis may also
be applied to the brain tumor pathogenesis. In con-
trast, Bachoo et al reported that not only neural stem
cells but also mature neural cells (astrocytes) were
equally capable of transformation upon INK4a and
ARF synergistic mutations14. These data support a
different point of view where deregulation of specific
genetic pathways, rather than cell-of-origin, dictates
the emergence and phenotype of brain cancers53.
Recently, a mouse model in which expression of
oncogenic K-ras is spatially and temporally controlled
was used to study the stem cell of origin of lung can-
cer. Lox-K-ras mice developed atypical adenomatous
hyperplasia that progressed to adenomas and then to
adenocarcinomas54. In Lox-K-ras tumors, a novel cell
type expressing both the AT2 cell-specific marker SP-
C and the Clara cell-specific marker CCA, termed
double-positive cells, were identified in adenomas,
particularly in lesions continuous with bronchiolar
hyperplasia. The study of their counterpart cells in
normal lung led to the identification of a regional pul-
monary stem cell population, termed bronchioalveo-
lar stem cells (BASCs), at the bronchioalveolar duct
junction. BASCs exhibited self-renewal potential,
were multipotent in clonal assays and most remark-
ably, expanded in response to oncogenic K-ras in cul-
ture and in precursors of lung tumors in vivo55.
These data point to BASCs as the putative cells of ori-
gin for lung adenocarcinoma. 
In 2004, Houghton et al published a controversial
study supporting that gastric cancer is originated not
from epithelial cells of the stomach but from bone
marrow-derived cells that are recruited after
Helicobcter infection to repair the microbe-induced
damage56. These bone marrow cells progressed
through metaplasia and dysplasia to ultimately form
epithelial cancer. Although this report further sup-
ports the well-accepted concept that chronic inflam-
mation fosters cancer development, the results indi-
cate that gastric tumors might arise from visiting
bone marrow cells rather than from the transforma-
tion of local tissue-specific cells. In fact, Helicobacter
pylori infection causes malignant transformation of
the gastric mucosa-associated lymphoid tissue (MALT),
leading to the generation of MALT lymphoma
through activation of NF-κB pathway57-61. However,
because bone marrow cells can adopt the phenotype
of other cells by spontaneous fusion, this might have
been the originating cause of this model of gastric
cancer62. More evidence is needed to prove any of
these hypotheses in gastric cancer and in other in-
flammatory neoplasias. 
ONCOGENE AND TUMOR SUPPRESSOR GENE
NETWORKS REGULATE SOMATIC
AND CANCER STEM CELLS
Disruption of critical self-renewal pathways
Cancer can be primarily considered as an alteration
of the stem cell self-renewal pathway. Thus, it is not
surprising that several genes that control normal
stem-cell self-renewal can cause cancer when dereg-
ulated by mutations. WNT signaling pathway regu-
lates proliferation and self-renewal of different or-
gans whereas activating mutations of WNT proteins
have been identified in a variety of cancers63-65.
Other signaling pathways involved in stem cell self-
renewal include Notch, Sonic hedgehog (Shh), phos-
phatidylinositol-3 kinase (PIK3), and Homeobox (HOX)
and Polycomb families, all of which are deregulated
in hematopoietic and epithelial tumors64,66-72. A cru-
cial task for investigators is to search for genetic and
functional similarities and differences between nor-
mal and cancer stem cell self-renewal pathways. 
BMI1 is a gene member of the Polycomb Group fami-
ly that has been involved in cancer72. In mouse mod-
els, forced expression of BMI1 in lymphocytes pro-
vokes lymphoma73 whereas BMI1 is amplified and
over-expressed in human mantle cell lymphoma74
specially in Ki67+ proliferating cells75. BMI1 deletion
in mice causes defects in hematopoiesis, neurological
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development and body growth76. BMI1 acts through
repressing two cyclin-dependent kinase inhibitors,
P16/INK4a and P14/ARF77. Two simultaneous re-
ports showed that BMI1 has an essential role in regu-
lating the proliferation of both normal and leukemic
stem cells78,79. In addition, BMI1 is also required for
the self-renewal of stem cells in the peripheral and
central nervous system80. These studies demonstrate
that BMI1 presents similar functions in cancer and
normal stem cells, yet its altered expression in stem
cells may lead to tumorigenesis through disruption of
genes (INK4a and ARF among others) that regulate
cell cycle control, apoptosis and DNA repair path-
ways.
However, a recent study challenges this concept and
supports the existence of genes or pathways that have
different effects on normal and cancer stem cells. The
tumor suppressor PTEN is a phosphatase that nega-
tively regulates signaling through the PI3K pathway,
inhibiting survival and proliferation81. Inactivation of
PTEN has been reported in many cancer types, in-
cluding lymphoid and myeloid leukemias81-84. Mice
with conditional deletion of PTEN gene in adult HSCs
developed myeloproliferative disease within days that
evolved to transplantable leukemia within weeks. In
contrast, normal HSCs without PTEN were progres-
sively depleted and were unable to stably reconstitute
irradiated mice after transplantation85,86. Thus, PTEN
inactivation leads to depletion of normal HSCs but
promotes the generation and expansion of leukemia-
initiating cells. Most importantly, authors also de-
monstrated the potential therapeutic application of
the differences of PTEN function in normal and can-
cer stem cells85. In PTEN deficient mouse, the PI3K
pathway is constitutively activated, which in turn ac-
tivates the mammalian target of rapamycin (mTOR).
The drug rapamycin inhibits mTOR kinase activity87-89.
In the PTEN-deficient mice, rapamycin depleted
leukemia-initiating cells and rescued the capacity of
normal HSCs to provide long-term multilineage re-
constitution to irradiated mice. 
Telomerase activity and telomere length regulate
cancer stem cells
Normal human cells have two critical points that reg-
ulate their life span, the senescence and crisis phases.
Senescence is associated with telomere shortening
and cell cycle arrest. If cells bypass this stage, they
keep growing until telomeres become critically short
and cells enter crisis phase, characterized by chromo-
some instability and apoptosis90. To investigate the
role of stem cells as targets for neoplastic transforma-
tion, adult human mesenchymal stem cells (hMSC)
were transduced with the telomerase hTERT gene91.
Long-term cultures of hMSC-TERT+ cells were char-
acterized by progressive loss of contact inhibition, an-
chorage independence and formation of tumors in
immunodeficient mice. This transformation was as-
sociated with deletion of INK4a/ARF locus and KRAS
activating mutation91,92. More recently, two inde-
pendent groups have intriguingly reported the spon-
taneous malignant transformation of similar mes-
enchymal stem cells in vitro93,94. In one report,
hMSCs isolated from adipose tissue bypassed senes-
cence and crisis phases, after which 50% of the cells
kept proliferating, acquired chromosome instability
and were able of generating tumors in immunodefi-
cient mice93. The spontaneous transformation was
accompanied by loss of INK4a gene expression, MYC
alteration and high telomerase activity. Similar find-
ings were reported by Miura et al. using murine bone
marrow-derived mesenchymal stem cells, which re-
sulted in spontaneous fibrosarcoma formation94. The
transformation process was also associated with
chromosomal abnormalities involving MYC and up-
regulation of telomerase activity. The potential spon-
taneous transformation of somatic stem cells should
deserve further attention because of their potential
clinical use in tissue regenerative medicine.
In light of these previous reports, increased telom-
erase activity may be responsible, at least in part, for
the malignant transformation of human and murine
mesenchymal stem cells91-94. This finding is not to-
tally unexpected, as alterations in telomere length
and telomerase activity may facilitate cancer develop-
ment by regulating genomic stability and cell
lifespan95. In fact, a combination of shortened telom-
eres and increased telomerase activity is seen in most
hematological and solid tumors96 and mTERT trans-
genic mice with increased telomerase activity sponta-
neously develop cancer97. The best model to study
telomere functions in stem cells has been the
hematopoietic cell compartment95,98. With age, HSCs
lose telomeric DNA while maintaining detectable
telomerase activity, what seems a mechanism to limit
progressively the hematopoietic regeneration99. In
fact, long-term repopulating capacity of telomerase-
deficient murine HSCs is remarkably deficient100.
Notably, these defects are not repaired by Tert over-
expression in HSCs, indicating additional telomere-
independent factors that regulate HSC regenera-
tion101. Together, these data point out to a role of
telomeres in the regulation of HSC homeostasis102.
Two recent studies investigated the effects of telom-
erase and telomere length on epidermal stem cell
behaviour103,104. Using different constitutive and in-
ducible transgenic mouse models, authors demon-
strated that telomere length and telomerase activity
are independent determinants of the mobilization ef-
ficiency and proliferative capacity of epidermal stem
cells. Thus, telomere shortening inhibited mobiliza-
tion of stem cells out of their niche and resulted in
suppression of stem cell proliferation. In contrast,
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telomerase activation promoted stem cell mobiliza-
tion and proliferation. These findings may explain the
increased susceptibility of mTERT mice to develop
skin tumors and anticipate a critical role of telom-
erase and telomere length in the regulation of cancer
stem cells97,98,102.
Asymmetric division of stem cells and cancer
Stem cells fulfil their biological functions over the
lifespan of the organism, thus requiring tight regula-
tion of the self-renewal process. During early embry-
onic growth, stem cells divide symmetrically and
each daughter cell retains the properties of the
parental cell. The adult stem cells normally divide
asymmetrically, whereby one daughter cell retains
the properties of the parental stem cell and the other
daughter cell begins differentiation105. But how can
impairment of asymmetric division in stem cells lead
to tumorigenesis? Drosophila melanogaster is an ex-
cellent model organism for the study of cancer de-
velopment upon gene mutation71. One of the best
characterized examples is neuroblastoma, a tumor
originated from neuroblast stem cells. Normally,
Drosophila neuroblasts divide asymmetrically, a
process which is controlled by genes regulating cell
polarity and cell fate106,107. Using Drosophila as a
model, three recent studies have shown that the loss
of polarity and impairment of asymmetric division in
stem cells leads to tumorigenesis108-110. In these re-
ports, neuroblasts containing mutations in various
genes that control cell division (Raps, Mira, Numb,
Brat and Pros) developed aggressive tumors that
could be retransplanted into new hosts. Importantly,
asymmetric division was disrupted in mutant stem
cells, whereby both daughter cells grow and behave
like neuroblasts leading to the formation of tu-
mors108-110. This transformation was associated with
genome instability and centrosome alterations (fig. 2).
Together, these data indicate that invertebrate cells
rapidly develop cancer upon mutation of the asym-
metric division machinery, by adopting an aberrant
mode of symmetric division111.
Although there is no solid proof to link asymmetric
cell division deregulation and human cancer, there
are at least three examples that suggest this possibili-
DIVIDING
NORMAL STEM CELL
DIVIDING 
CANCER STEM CELL
Differenciated Cells
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Fig. 2. Asymmetric and symmetric stem cell division modes occurring stem cells.
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ty. The adenomatous polyposis coli (APC) gene is re-
quired for the asymmetric division of Drosophila
spermatogonial stem cells and it is also a critical tu-
mour suppressor in human colon cancer112-114. A hu-
man homologue of the Drosophila gene LgL is
HUGL1, which controls cell polarity and is common-
ly inactivated in cancer in humans and in mice115-117.
Last, inactivation of Numb may in turn activate the
Notch signalling pathway, commonly observed in hu-
man solid and hematopoietic tumors118,119. It may be
hypothesized that APC mutations occurring in intes-
tinal epithelial stem cells, HUGL1 or Numb alter-
ations may lead to cancer by altering asymmetric cell
division. The study of these and other human ho-
mologs of the Drosophila genes involved in the asym-
metric/symmetric cell division switch may provide
novel insights into human cancer development. 
Micro-RNAs as regulatory elements of cancer
stem cells
One of the key features of stem cells is their capacity
to divide for long periods of time while being in a
more quiescent state than their more proliferative
progeny. For that, cell cycle must be critically con-
trolled in stem cells. Recent studies have suggested a
role of the microRNA pathway in the regulation of
stem cell division120,121. MicroRNAs (miRNAs) are
small noncoding RNAs that regulate expression of
coding genes involved in the control of development,
proliferation and apoptosis, primarily through trans-
lational repression122,123. Remarkably, miRNAs are
deregulated by genomic alterations in cancer cells124,125,
thus targeting oncogenes and suppressor genes in an
aberrant manner126-129. One of the best characterized
examples is the miRNA cluster miR-17-92 in the chro-
mosome 13q31 amplicon, commonly observed in B-
cell lymphoma and different carcinomas123,130,131.
miR-17-92 over-expression appears to collaborate
with MYC in promoting tumorigenesis127,128.
Initial evidence connecting miRNAs, stem cells and
cancer was provided by Lu et al by classifying miRNA
expression patterns in 334 primary tumors of differ-
ent types and in normal tissues132. Notably, tumors
displayed a miRNA profile that was reminiscent of
that in the stem cells from which they were derived,
providing a better indicator of tissue lineage that the
conventional mRNA profiles. Overall, the expression
level for most miRNAs was significantly reduced in
the tumors while retaining expression of stem cell
miRNAs, including the miR-17-92 cluster. One of the
components of the miR-17-92 cluster, miR-19, has
been shown to down-regulate the tumor suppressor
PTEN133. which is directly implicated in stem cell de-
velopment85,86. It may be speculated that silencing of
PTEN as a consequence of the miR-19 over-expres-
sion observed in many lymphomas and carcinomas
may take place in tissue-specific stem cells, leading to
cancer development. Another example was provided
by Chen et al by showing that miR-181, which is pref-
erentially expressed in bone marrow B-lymphoid
cells, when ectopically expressed in hematopoietic
stem or progenitor cells leads to an increased fraction
of B-lineage that may ultimate cause malignancy134.
A recent study provided additional links between
miRNAs and the regulation of stem cells. The miR-
221 and miR-222 genes were shown to regulate
CD34+ stem cell proliferation and differentiation by
unblocking kit protein production at mRNA level,
thus leading to eryhtroleukemia135. More direct evi-
dence was provided by Hatfield et al, who deonstrat-
ed the necessity of the miRNA pathway for proper
control of germline stem cell division in Droso-
phila120. Analysis of these stem cells mutant for dicer-
1, the double-stranded RNaseIII essential for miRNA
biogenesis, revealed a marked reduction in the rate of
germline cyst production. These mutant stem cells
were defective in cell cycle control by delaying the G1
to S transition, thus making stem cells insensitive to
stop signals120. If this miRNA machinery is mutated,
it might contribute to tumor formation by promoting
cell cycling and proliferation. Because silencing of
miRNAs in vivo with «antagomirs» have been suc-
cessfully used to treat disease in mouse models136.
understanding the role of the miRNA pathway in the
regulation of stem cell division may provide new op-
portunities for cancer treatment.
Tumor progenitor genes and epigenetic
origin of cancer
It is widely accepted that cancer includes a heteroge-
neous group of disorders caused by a series of clonal-
ly selected genetic and epigenetic changes in onco-
genes and tumor suppressor genes1,2. However, a
recent theory suggests that cancer originates from a
polyclonal epigenetic alteration of stem and progeni-
tor cells within specific tissues, initially producing a
pre-neoplastic epigenetically aberrant state137. Sub-
sequently, an initiating mutation (specific activation
of oncogenes in leukemia and sarcoma or inactiva-
tion of tumor suppressor genes in most solid tumors)
targets a subpopulation of the epigenetically disrupt-
ed progenitor cells, thus leading to cancer develop-
ment. A third stage would involve the acquisition of
additional genetic and epigenetic changes that pro-
mote tumor progression and metastasis137. The epi-
genetic progenitor origin of human cancer hypothesis
is based on several observations. First, epigenetic
changes (global hypomethylation and specific gene
promoter methylation) are detected early in tumori-
genesis and what is more relevant, even in normal
tissues before tumors arise138-140. Second, loss of ge-
nomic imprinting (parent-of-origin-specific gene si-
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lencing of a specific gene) is a different epigenetic
mechanism that causes reduction or absence of ex-
pression of a specific allele of a gene in somatic cells
of the offspring. Loss of imprinting (LOI) of the insu-
line-like growth factor 2 (IGF2) gene is observed in
50% of Wilms tumors and is associated with fivefold
increased frequency of colorectal neoplasias141-144.
Consequently, LOI of IGF2 might cause cancer by in-
creasing the progenitor cell population in the kidney
in Wilms tumor and in the gastrointestinal tract in
colorectal cancer. According to this theory, authors
define tumor-progenitor genes as those that suffer
epigenetic modification in stem cells thus promoting
malignant transformation137. Examples of these tu-
mor progenitor genes are, in addition to IGF2, the
POU transcription factor OCT4 or the forkhead tran-
scription factor FOXD3, whose inappropriate expres-
sion could augment proliferation and block differenti-
ation in stem cells145,146. One additional example
may be represented by two DNA repair genes, ataxia
teleangiectasia mutated (ATM) and checkpoint kinase
2 (CHK2), frequently inactivated in mantle cell lym-
phoma. This B-cell lymphoma is characterized by the
chromosomal translocation t(11;14)(q32;q21) that
causes deregulation of cyclin D1 oncoprotein and is
thought to be the earliest mutation in the disease147.
In more than 50% of cases, genomic deletion or muta-
tion of ATM or CHK2 genes accumulate to the initial
t(11;14)75,148,149. Notably, in a small subset of patients
with mantle cell lymphoma, germline mutations of
ATM or CHK2 have been observed, indicating that
this alterations preceded and may have conditioned
the acquisition of the t(11;14)148,149. According to the
epigenetics theory, ATM or CHK2 (and perhaps other
DNA repair genes) might become silenced by epige-
netic mechanisms (promoter hypermethylation, LOI)
in a polyclonal stem or progenitor cell population.
These stem/progenitor cells with damage of the DNA
repair machinery would not control properly the
physiological process of immunoglobulin gene re-
arrangement in early B-cells properly, thus causing
aberrant chromosomal translocations that will pro-
mote lymphoma formation. Because the evidences
supporting the epigenetic origin of cancer are still cir-
cumstantial, further experimental work will deter-
mine whether this interesting model is, at least in
part, implicated in cancer development.
THE STEM CELL NICHE AS A MASTER
REGULATOR OF CANCER FORMATION
Normal somatic and cancer stem cells not only share
the capacities of self-renewal and multi-lineage dif-
ferentiation, but are also similarly surrounded by a
specialized cell microenvironment, termed the stem
cell niche. The niche is the physical anchoring site for
stem cells composed of cells that function to maintain
and regulate stem cells homeostasis150. Adhesion
molecules are also involved in the interaction be-
tween stem cells in their niche and the extracellular
matrix. The niche regulates stem cell behaviour
through providing extrinsic signals that balance stem
cell proliferation, differentiation and symmetric/
asymmetric cell division. In addition, it has been pro-
posed that the stem cell niche functions to prevent tu-
morigenesis by regulating self-renewal and prolifera-
tion rate in stem cells. Thus, intrinsic mutation in the
niche may promote cancer development5,151. Fur-
thermore, the molecular machinery used by normal
stem cells for homing to or mobilizing from the niche
may be utilized by cancer stem cells for invasion and
metastasis151.
Still, the idea of cancer as a consequence of stem cell
niche mutations is hypothetical, although recent data
support the role of the vascular niche in initiating
metastasis152. In addition, skin tumors can be caused
by telomerase activation, which promotes epidermal
stem cell mobilization out of their niche together with
increased cell proliferation97,103. The study of sig-
nalling pathways that control mobilization and hom-
ing of stem cells in the niche will enhance our under-
standing of cancer development, invasiveness, and
metastasis. Furthermore, if cancer stem cells depend
on their niche to survive, targeting the cell compo-
nents of the niche may result in therapies that com-
plement those targeting directly the cancer stem
cells150.
DO LYMPHOID MALIGNANCIES ARISE FROM
MUTATIONS THAT DEREGULATE SOMATIC
STEM CELLS?
In contrast to myeloid neoplasias, the identity of the
stem cells responsible for the initiation and mainte-
nance of lymphoid malignancies has not been re-
solved. Yet, lymphocyte lineage development, which
follows a tightly regulated, hierarchical order which
also permits a great flexibility, has been well charac-
terized during the last years153-156. HSCs early differ-
entiate to multipotent progenitors (MMP), which have
lost long-term self-renewal capacity and are commit-
ted to either the lymphoid (common lymphoid pro-
genitor or CLP) or myeloid (common myeloid pro-
genitor or CMP) lineages. CLPs are restricted to
lymphoid development, giving rise to B cells, T cells,
dendritic cells and natural killer cells. These develop-
mental steps are controlled by diverse cytokines and
transcription factors cooperating to achieve efficient
generation of mature lymphocytes154. In early stages,
both PU.1 and Ikaros control the balance between
myeloid or lymphoid commitment of MMPs through
regulation of different signaling receptors (FLT3, c-
KIT and IL-7R)157-159. More committed, earliest B cell
progenitor transition to pro-B cell depends on addi-
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tional transcription factors (E2A, EBF, PAX5 and
BCL11A), which coordinately activate appropriate B-
cell expression programs and immunoglobulin heavy-
chain gene rearrangements160-165. (fig. 3). Alternati-
vely, CLPs can differentiate to T-cells through Notch1
activation, which is negatively regulated by PAX5166-168.
Recent studies have shown the role of FOXP1 in the
transition of pro-B cells to pre-B cells, a step which is
also controlled by IRF4/MUM1 and IRF8169,170. More
differentiated B-cells are also tightly programmed by
transcription factors. OBF1 and Aiolos are crucial for
the transition of pre-B cells to immature B cells ex-
pressing BCR, as well as for the mobilization of im-
mature B-cells from bone marrow to the spleen,
whereas NF-κB activation has essential roles in the
transition of immature to mature B-cells171-173.
Additionally, BCL6, IRF4, BLIMP1, XBP1 and PAX5
are involved in the terminal differentiation of B-cells
into plasma cells174-182.
Chromosomal translocations in lymphoid malignan-
cies usually juxtapose the immunoglobulin or T-cell
receptor genes with a variety of oncogenes which re-
sult deregulated183,184. Notably, many of the genes in-
volved in the lymphocyte developmental network are
targeted in such chromosomal translocations, namely
PAX5, OBF1, BCL11A, BCL6, IRF4/MUM1, Ikaros,
NOTCH1 and FOXP1 (table 1)155,164,183,185-191. Other
regulatory genes are also altered through alternative
genetic mechanisms, such as gene amplification of
the NF-κB family gene REL, activating mutation of
NOTCH1 and inactivating mutation of BLIMP1119,192-194.
Although these genetic rearrangements are thought
to be early events in the lymphoma pathogenesis,
transgenic mouse models for the lymphoma onco-
genes have shown a great heterogeneity in driving
malignancy in vivo. Thus, while mice with deregulat-
ed expression of MYC develop tumors displaying fea-
tures typical of human Burkitt lymphoma, other mod-
els did not generate lymphoma spontaneously or
developed tumors that did not resemble human dis-
ease195-201. A possible explanation for the failure of
this mouse models could be the necessity to express
the aberrant oncogene into the adequate stem or pro-
genitor cells to generate human-like lymphoma.
Recent evidence supports this hypothesis. A trans-
genic mouse model where expression of BCL6 onco-
gene was restricted to the somatic stem cell compart-
ment developed diffuse large B cell lymphoma that
mimicked human disease (Pérez-Caro and Sánchez-
García, abstract AACR 2006). This lymphoma could
only be propagated to secondary recipients by stem
cells expressing BCL6. Moreover, gene expression
patterns of stem cells expressing BCL6 showed a
BCL6 signature and established a B-cell differentia-
tion program. These results indicate that BCL6 onco-
gene is capable of driving a specific genetic program
in stem cells that mediate their transformation into
lymphoma cells. This concept is reinforced by NOTCH1,
an essential regulator of T cell lineage development.
More than 50% of human T-cell acute lymphoblastic
leukemias, including all major molecular oncogenic
subtypes, have activating mutations of NOTCH1
gene119. Notably, constitutively activated forms of the
NOTCH1 receptor are potent inducers of T cell acute
lymphoblastic leukemia/lymphoma when expressed
in murine bone marrow stem cells202. The mecha-
nism by which NOTCH1 induces T-cell malignancy
in stem cells appears to be an increase in their self-
renewal and proliferative properties202,203. Theoretica-
lly, other transcription factors controlling lymphocyte
fate could, like BCL6 and NOTCH1, drive malignancy
when mutated in stem cells.
Lineage commitment of lymphoid cells has been gen-
erally considered an irreversible process, but a recent
challenging report by Xie et al. showed that enforced
expression of C/EBPα/β transcription factors in differ-
entiated B-cells leads to their reprogramming into
macrophages by inhibiting PAX5 and synergizing
with PU.1204. This exceptional lymphoid plasticity
might be also observed in lymphoma, as mutations in
differentiated B or T cell lymphocytes may reprogram
them into de novo stem-like cells. In support of this
hypothesis, a recent report describes the mechanisms
for B-cell lymphocyte reprogramming in malignan-
cy205. Hodgkin and Reed-Sternberg (HRS) cells, the
tumor cells in classical Hodgkin lymphoma, derive
from mature B cells but have largely lost their B-cell
phenotype. This extensive reprogramming is experi-
mentally caused by the inhibition of the transcription
factor E2A in HRS cells205. These data conclude that
the plasticity of mature human lymphoid cells upon
mutation may contribute to cancer development. A
different approach was used to investigate the cells of
origin of multiple myeloma, a clonal B-cell neoplasm
that affects terminally differentiated B cells (plasma
cells)206. Among the CD138+ myeloma plasma cells,
a more immature and rare cell subpopulation that
lacked CD138 expression was responsible for initia-
tion and maintenance of the disease29,207. These cells,
which resembled post-germinal center B cells rather
than fully differentiated plasma cells, may represent
the cancer stem cells of origin of myeloma. 
CANCER STEM CELLS FROM A THERAPEUTIC
PERSPECTIVE
Hypothetically, conventional chemotherapy kills the
rapidly proliferating tumor cells whereas cancer stem
cells remain viable during treatment because of their
relative quiescence208. Thus, when treatment ceases,
cancer stem cells regenerate the tumor entirely, ex-
plaining why cancer can relapse in patients in com-
plete remission3,4,49. Consequently, destruction of the
stem cell population capable of initiating and main-
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taining tumors challenges the treatment of human
malignancies. But to date, there is only circumstantial
evidence, and even contradictory, of this selective re-
sistance of cancer stem cells to chemo- or radiothera-
py. Normal tissue-specific stem cells, including HSCs,
are more resistant to chemotherapy than mature cells
from the same tissues. It can relate to the higher ex-
pression of drug-resistance proteins such as MDR1
and ABC transporters in stem cells, which might
make them less sensitive to chemotherapy and apop-
tosis induction209,210. Supporting this concept, forced
expression of the anti-apoptotic gene BCL2 in mouse
hematopoietic stem cells makes them more resistant
to radiotherapy211. A number of studies have evaluat-
ed that cancer stem cells, resembling normal stem
cells, may be highly resistant to standard chemother-
apy. Costello et al reported that CD34+CD38- AML
stem cells presented reduced in vitro sensitivity to the
chemotherapeutic agent daunorubicin compared to
other AML cell populations and to normal HSCs as
well212. In contrast, Guzman and colleagues demon-
strated that idarubicine (a daunorubicin analog) com-
bined with the drug MG-132 selectively killed
CD34+CD38- AML stem cells but not normal HSCs213.
This apparently contradictory results may simply indi-
cate that cancer stem cells are either sensitive or re-
sistant to the different chemotherapeutic combinations.
In fact, cancer stem cell sensitivity can also vary even
with specific molecular-directed therapies. Imatinib,
a potent tyrosine kinase inhibitor of the BCR-ABL
protein, has replaced interferon-alpha as the standard
therapy of patients with CML214,215. However, ongo-
ing clinical trials have not shown a clear survival
benefit for the use of imatinib vs interpheron-al-
pha216. Indeed, recent data suggest that imatinib may
not achieve complete ablation of CML cells217, and
even patients with CML who present complete mo-
lecular response almost invariably relapse when the
drug is discontinued216,218. These observations may
be explained by in vitro findings suggesting that ima-
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tinib, which is very active against differentiated CML
progenitors, shows limited activity against CML stem
cells219-221. Unequivocal in vivo proof of the resist-
ance of leukemic stem cells to imatinib was recently
provided by Sanchez-Garcia et al222. A transgenic
mouse model where expression of BCR-ABL-p210
was restricted to the somatic stem cell compartment
led to development of CML that spontaneously
evolved to blast crisis, thus mimicking human dis-
ease. Notably, imatinib treatment of these mice was
not associated with clinical survival benefit, whereas
CML stem cells expressing BCR-ABL were shown to
be resistant in vivo to the drug (fig. 4). This mouse
model may be useful not only to investigate imatinib
responses in CML but also to test novel more potent
BCR-ABL tyrosine-kinase inhibitors223,224.
On the contrary, there are examples of successful
eradication of cancer stem cells after targeting appro-
priate transforming mutated pathways85. As dis-
cussed above, PTEN inactivation in mice leads to de-
pletion of normal HSCs but promotes the expansion
of leukemia-initiating cells, thus leading to myeloid
leukemia85,86. PTEN deficiency activates PI3K path-
way, which in turn activates mTOR. Rapamycin is an
active drug that inhibits mTOR kinase activity, and
patients with acute leukemia respond to this
drug87,88. In the PTEN-deficient mice, rapamycin suc-
cessfully eradicated leukemia by depleting leukemia-
initiating cells and rescuing the capacity of normal
HSCs to provide long-term multilineage reconstitu-
tion. A second molecular therapeutic target in
leukemia is NOTCH1, which induces T-cell malig-
nancy in stem cells by increasing their self-renewal
and proliferative capacities, and is activated in more
than half of the patients with T-cell ALL119,202,203.
Interestingly, inhibitors of the proteolytic enzyme γ-se-
cretase are active in NOTCH1-mutated T-cell leuke-
mia/lymphoma, and therapeutic clinical trials using
this drug are now under development. Like these
therapeutic agents (rapamycin, inhibitors of γ-secre-
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tase), to find other drugs that specifically target the
defective pathways in cancer stem cells without dam-
aging normal stem cells is a major goal in the battle
against cancer.
CONCLUSIONS
The cancer stem cell hypothesis proposes that most
cancers derive from tissue-specific stem cells or their
immediate progeny through mutations that deregu-
late their self-renewal and differentiation pathways.
Because stem cells are exposed to various tumori-
genic agents throughout their lifetime, the ageing
stem cell may represent a major target of malignant
transformation. Solid demonstration of the existence
of cancer stem cells has been shown in myeloid
leukemia and in a subset of solid tumors, which rep-
resent a minority of human cancers. In addition, can-
cer stem cells have been defined by their functional
capacity to form tumors in immunocompromised
mice rather than by specific genetic studies. Detailed
isolation and molecular characterization of all tissue-
specific cancer stem cells should be a major task not
only to better understand cancer biology but also to
improve current treatments. Novel therapies should
be designed to specifically target molecules or path-
ways damaged in cancer stem cells but not in normal
cells. These efforts might result in higher cure rates
for patients with cancer.
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